Ahead of an FDA decision date later this year, Lexicon Pharmaceuticals is trimming its workforce.
The company will lay off roughly half of its sales and commercial teams, it announced Tuesday, affecting about 75 people. Lexicon said the move will help it prepare for commercial activities for sotagliflozin in type 1 diabetes and chronic kidney disease, and will “right-size” that work for the approved version of sotagliflozin, the heart failure drug known as Inpefa.
Mike Exton
“We strongly believe in the value Inpefa offers patients, and we will continue to drive growth in heart failure with a targeted approach,” CEO Mike Exton said in a statement.
Lexicon resubmitted its approval request for type 1 diabetes and chronic kidney disease in June and said it expects a six-month review period, with a potential launch coming in early 2025. The cost-cutting will also help Lexicon fund a Phase 3 study for sotagliflozin
